Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma-Reference-Cited by-同舟云学术

Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma

Published:2024-05-30 Issue:11 Volume:16 Page:2084
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Luijten Maartje M. W.¹²,van Weelden Willem Jan¹³,Lalisang Roy I.⁴,Bulten Johan⁵,Lindemann Kristina⁶⁷,van Beekhuizen Heleen J.⁸^ORCID,Trum Hans⁹,Boll Dorry¹⁰,Werner Henrica M. J.¹¹^ORCID,van Lonkhuijzen Luc R. C. W.¹²^ORCID,Yigit Refika¹³,Krakstad Camilla¹⁴^ORCID,Witteveen Petronella O.¹⁵,Galaal Khadra¹⁶,van Ginkel Alexandra A.²,Bignotti Eliana¹⁷^ORCID,Weinberger Vit¹⁸¹⁹^ORCID,Sweegers Sanne¹,Eriksson Ane Gerda Z.⁶⁷^ORCID,Keizer Diederick M.²⁰,van de Stolpe Anja²¹,Romano Andrea⁴¹¹^ORCID,Pijnenborg Johanna M. A.¹^ORCID,

Affiliation:

1. Department of Obstetrics and Gynaecology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands

2. Department of Gynaecology, Rijnstate Hospital, 6815 AD Arnhem, The Netherlands

3. Department of Obstetrics and Gynaecology, Canisius Wilhelmina Hospital, 6532 SZ Nijmegen, The Netherlands

4. GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 ER Maastricht, The Netherlands

5. Department of Pathology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands

6. Division of Medicine, Department of Gynecological Oncology, Oslo University Hospital, 0424 Oslo, Norway

7. Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway

8. Department of Gynecologic Oncology, Erasmus MC Cancer Institute, Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands

9. Center for Gynecologic Oncology Amsterdam, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands

10. Department of Gynaecology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands

11. Department of Obstetrics and Gynecology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands

12. Department of Gynaecology and Obstetrics, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands

13. Department of Obstetrics and Gynecology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands

14. Department of Gynecology and Obstetrics, Haukeland University Hospital, 5009 Bergen, Norway

15. Department of Medical Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands

16. Sultan Qaboos Comprehensive Cancer Center, Muscat P.O. Box 566 PC 123, Oman

17. Division of Obstetrics and Gynecology, A. Nocivelli Institute for Molecular Medicine, ASST Spedali Civili di Brescia, 25123 Brescia, Italy

18. Department of Obstetrics and Gynecology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic

19. Department of Obstetrics and Gynecology, University Hospital Brno, 625 00 Brno, Czech Republic

20. InnoSIGN, 5656 AE Eindhoven, The Netherlands

21. DCDC-Tx B.V., 5263 EM Vught, The Netherlands

Abstract

Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC can vary by tumour location and is frequently lost with tumour progression. Therefore, we explored the relationship between ER/PR-IHC expression and tumour location in EC. Methods: Pre-treatment tumour biopsies from 6 different sites of 80 cases treated with hormonal therapy were analysed for ER/PR-IHC expression and classified into categories 0–10%, 10–50%, and >50%. The ER pathway activity score (ERPAS) was determined based on mRNA levels of ER-related target genes, reflecting the actual activity of the ER receptor. Results: There was a trend towards lower PR-IHC (33% had PR > 50%) and ERPAS (27% had ERPAS > 15) in lymphogenic metastases compared to other locations (p = 0.074). Hematogenous and intra-abdominal metastases appeared to have high ER/PR-IHC and ERPAS (85% and 89% ER-IHC > 50%; 64% and 78% PR-IHC > 50%; 60% and 71% ERPAS > 15, not significant). Tumour grade and previous radiotherapy did not affect ER/PR-IHC or ERPAS. Conclusions: A trend towards lower PR-IHC and ERPAS was observed in lymphogenic sites. Verification in larger cohorts is needed to confirm these findings, which may have implications for the use of hormonal therapy in the future.

Funder

InnoSIGN

Publisher

MDPI AG

Link

https://www.mdpi.com/2072-6694/16/11/2084/pdf

Reference50 articles.

1. Cancer of the corpus uteri;Amant;Int. J. Gynaecol. Obstet.,2018

2. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies;Renehan;Lancet,2008

3. Cancer statistics, 2008;Jemal;CA Cancer J. Clin.,2008

4. National Cancer Institute (2024, May 27). Cancer Stat Facts: Uterine Cancer. Surveillance, Epidemiology, and End Results Program Cancer Statistics Review 2014–2020, Available online: https://seer.cancer.gov/statfacts/html/corp.html#.Xx63P5vaNyU.link.

5. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial;Trovik;Eur. J. Cancer,2013